To test this hypothesis, MDA-MB231 breast cancer cells (parental or stably expressing HA-tagged SHARP1) were treated with the proteasome inhibitor MG132, and SHARP1 levels were examined by immunoblotting. The gene discussed is BHLHE41; the disease is breast carcinoma.